Artal Group’s Jade Biosciences JBIO Stock Holding History

Artal Group’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-23,131	Closed	-$1.34M	–	12
2024 Q2	$1.34M	Buy	+23,131	New	+$15.3M	0.03%	84

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Artal Group's JBIO Position: Q3 2024 in Review

Artal Group sold out of Jade Biosciences (JBIO) in Q3 2024, closing a stake of 23,131 shares — an estimated $1.34M sold.

Artal Group first reported a position in JBIO in Q2 2024 and held it in 1 quarter. The position peaked at $1.34M in Q2 2024. 72 funds tracked by Wall St. Rank hold JBIO as of Q3 2024.

Artal Group reported no remaining Jade Biosciences position as of Q3 2024 after selling out during the quarter.
Artal Group sold 23,131 Jade Biosciences shares in Q3 2024, an estimated $1.34M.
Artal Group first reported a position in Jade Biosciences in Q2 2024 and held it in 1 quarter.
Artal Group's Jade Biosciences position peaked at $1.34M in Q2 2024.
72 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.